Scioderm begins Phase III registration trial of Zorblisa to treat epidermolysis bullosa

US-based biopharmaceutical firm Scioderm has started a Phase III registration trial (SD-005) of its new topical therapy, Zorblisa (SD-101), to treat blisters and lesions in patients with Epidermolysis Bullosa (EB), a rare genetic connective tissue di…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news